[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Small Case Series
Dec 2012

Epidermal Growth Factor Receptor Inhibitors for Treatment of Orbital Squamous Cell Carcinoma

Author Affiliations

Author Affiliations: Section of Ophthalmology (Drs El-Sawy and Esmaeli) and Departments of Head and Neck Surgery (Drs El-Sawy, Myers, and Esmaeli) and Thoracic/Head and Neck Medical Oncology (Drs Sabichi, Kies, William, Glisson, and Lippman), The University of Texas MD Anderson Cancer Center, Houston.

Arch Ophthalmol. 2012;130(12):1608-1611. doi:10.1001/archophthalmol.2012.2515

Orbital and periorbital squamous cell carcinomas (SCCs) are treated with surgical resection as the primary modality and radiation therapy as adjuvant treatment in patients with perineural invasion or concerns for microscopically positive margins. For advanced cases, extensive surgery such as orbital exenteration may be needed to fully extirpate the tumor. Orbital exenteration leads to loss of the eye and significant facial disfigurement but has the potential to produce long-term cure. The extensive surgical treatments required for advanced cases of orbital and periorbital SCC entail long periods of general anesthesia and inpatient hospitalization; thus, in patients with poor performance status, advanced age, or multiple medical comorbidities, surgery may not be the best option.